Implication of fibrate therapy for homocysteine.
Jonkers
I J
IJ
de Man
F H
FH
Onkenhout
W
W
van der Laarse
A
A
Smelt
A H
AH
D001629:Bezafibrate / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood / Q000652:urine; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D015228:Hypertriglyceridemia / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008297:Male
D000960:Hypolipidemic Agents; D008055:Lipids; D006710:Homocysteine; D003404:Creatinine; D001629:Bezafibrate